KR102142164B1 - 퀴논 화합물 및 암의 치료를 위한 그것의 용도 - Google Patents

퀴논 화합물 및 암의 치료를 위한 그것의 용도 Download PDF

Info

Publication number
KR102142164B1
KR102142164B1 KR1020157002128A KR20157002128A KR102142164B1 KR 102142164 B1 KR102142164 B1 KR 102142164B1 KR 1020157002128 A KR1020157002128 A KR 1020157002128A KR 20157002128 A KR20157002128 A KR 20157002128A KR 102142164 B1 KR102142164 B1 KR 102142164B1
Authority
KR
South Korea
Prior art keywords
cancer
pharmaceutical composition
delete delete
diaphorase
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157002128A
Other languages
English (en)
Korean (ko)
Other versions
KR20150036215A (ko
Inventor
앨런 맥고원
존 해드필드
존 버틀러
Original Assignee
온코-엔엑스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코-엔엑스 리미티드 filed Critical 온코-엔엑스 리미티드
Publication of KR20150036215A publication Critical patent/KR20150036215A/ko
Application granted granted Critical
Publication of KR102142164B1 publication Critical patent/KR102142164B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157002128A 2012-07-30 2013-07-30 퀴논 화합물 및 암의 치료를 위한 그것의 용도 Expired - Fee Related KR102142164B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1213486.2A GB201213486D0 (en) 2012-07-30 2012-07-30 Quinone compounds and their uses for the treatment of cancer
GB1213486.2 2012-07-30
PCT/EP2013/065968 WO2014020012A1 (en) 2012-07-30 2013-07-30 Quinone compounds and their uses for the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20150036215A KR20150036215A (ko) 2015-04-07
KR102142164B1 true KR102142164B1 (ko) 2020-08-06

Family

ID=46881339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002128A Expired - Fee Related KR102142164B1 (ko) 2012-07-30 2013-07-30 퀴논 화합물 및 암의 치료를 위한 그것의 용도

Country Status (16)

Country Link
US (1) US9266829B2 (enExample)
EP (1) EP2882743B1 (enExample)
JP (1) JP6317742B2 (enExample)
KR (1) KR102142164B1 (enExample)
CN (1) CN104583200B (enExample)
AU (1) AU2013298653B2 (enExample)
BR (1) BR112015001837B1 (enExample)
CA (1) CA2880021C (enExample)
DK (1) DK2882743T3 (enExample)
ES (1) ES2662917T3 (enExample)
GB (2) GB201213486D0 (enExample)
IN (1) IN2015DN01223A (enExample)
MX (1) MX361650B (enExample)
NO (1) NO2882743T3 (enExample)
RU (1) RU2688675C2 (enExample)
WO (1) WO2014020012A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115887684B (zh) * 2022-12-02 2025-02-14 南京邮电大学 基于dna折纸和阿霉素前药构筑的递药纳米体系及方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156744A (en) * 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
EP1784172A4 (en) * 2004-06-21 2007-12-19 Hutchison Medipharma Entpr Ltd CANCER CHEMOTHERAPY
BRPI0808804A2 (pt) * 2007-03-13 2014-08-19 Spectrum Pharmaceuticals Inc Administração de apaziquona intravesical seguindo ressecção transuretral para tratamento de câncer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chem. Pharm. Bull., 1972, 20, 1968-1979.*
Journal of Chromatography B, 1999, 729, 287-295.*

Also Published As

Publication number Publication date
NO2882743T3 (enExample) 2018-05-12
EP2882743A1 (en) 2015-06-17
AU2013298653A1 (en) 2015-02-19
GB2519004A (en) 2015-04-08
AU2013298653B2 (en) 2017-10-19
MX361650B (es) 2018-12-13
CN104583200A (zh) 2015-04-29
HK1209111A1 (zh) 2016-03-24
BR112015001837B1 (pt) 2021-11-16
CN104583200B (zh) 2017-07-25
GB201213486D0 (en) 2012-09-12
IN2015DN01223A (enExample) 2015-06-26
ES2662917T3 (es) 2018-04-10
WO2014020012A1 (en) 2014-02-06
KR20150036215A (ko) 2015-04-07
BR112015001837A2 (pt) 2017-07-04
RU2015105036A (ru) 2016-09-20
JP6317742B2 (ja) 2018-04-25
CA2880021C (en) 2020-01-14
CA2880021A1 (en) 2014-02-06
GB2519004B (en) 2016-03-30
US9266829B2 (en) 2016-02-23
JP2015524815A (ja) 2015-08-27
MX2015000969A (es) 2015-09-23
EP2882743B1 (en) 2017-12-13
US20150210639A1 (en) 2015-07-30
RU2688675C2 (ru) 2019-05-22
DK2882743T3 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
Sangshetti et al. Antileishmanial drug discovery: Comprehensive review of the last 10 years
Chen et al. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors
Shukla et al. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2
US20090209482A1 (en) Azacytidine analogues and uses thereof
US20200115358A1 (en) Icariin and icaritin derivatives
Chugunova et al. Novel structural hybrids on the base of benzofuroxans and furoxans. Mini-review
JP2016502981A (ja) ムチンが関与する疾患の処置
JP2013231065A (ja) 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
TW201609094A (zh) 治療癌症之新穎方法
Zhang et al. Mitochondria-targeting natural product rhein conjugated with dichloroacetate as the dual inhibitor of glycolysis and oxidative phosphorylation to off energize cancer cells and induce ROS storm
US20240398823A1 (en) Dual inhibitor of histone deacetylase 6 and heat shock protein 90
US10774063B2 (en) Materials and method for inhibiting replication protein A and uses thereof
KR102142164B1 (ko) 퀴논 화합물 및 암의 치료를 위한 그것의 용도
JP2019510084A (ja) 小分子型の活性酸素種誘導剤及びミトコンドリア活性阻害剤
EP2870135A1 (en) Pharmaceutical composition comprising amino-phenyl- acetic acid octadec-(z)-9-enyl ester and use thereof for treating tumors
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
CN115814095A (zh) Rad51抑制剂和抗癌治疗剂的组合
CN1615127A (zh) 取代的二环[3.3.1]壬烷－2,4,9三酮作为活性药物成分
US20230181564A1 (en) Potent Tetrahydroquinolone Eliminates Apicomplexan Parasites
RU2487883C2 (ru) Аналоги азацитидина и их применение
Patyka Interplay between O6-Methylguanine-DNA Methyltransferase (MGMT) and p53 in Glioblastoma: Implications for Response to p53-targeting Compound PRIMA-1MET (APR-246) and Ionizing Radiation
HK1229695A1 (en) Novel methods for treating cancer
HK1191561B (en) Treatment of solid tumours

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230801

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230801